Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

Comi, G; Abramsky, O; Arbizu, T; Boyko, A; Gold, R; Havrdová, E; Komoly, S; Selmaj, K; Sharrack, B; Filippi, M

Comi, G; Abramsky, O; Arbizu, T; Boyko, A; Gold, R; Havrdová, E; Komoly, S; Selmaj, K; Sharrack, B; Filippi, M.

Affiliation

Comi G; Department of Neurology, University Vita-Salute and Scientific Institute San Raffaele, Milan, Italy. comi.giancarlo@hsr.it

Mult Scler ; 16(11): 1360-6, 2010 Nov.

Article in En | MEDLINE | ID: mdl-20834039

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolones / Multiple Sclerosis, Relapsing-Remitting / Immunologic Factors Type of study: Clinical_trials Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2010 Document type: Article Affiliation country: Italia Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google